PaxMedica (PXMD) Stock Price, News & Analysis

Company Overview

PaxMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodevelopmental disorders and other conditions with significant unmet medical needs. The company’s research has centered on therapies intended to address symptoms and underlying biological mechanisms associated with these disorders.

PaxMedica’s primary product candidate is PAX-101, an intravenous formulation of suramin, an established antiparasitic compound. The company has evaluated PAX-101 in clinical studies for autism spectrum disorder and has also explored its potential in other neurodevelopmental conditions, including Fragile X syndrome and Phelan-McDermid syndrome.

In addition to its neurodevelopmental research, PaxMedica has pursued opportunities involving suramin in infectious disease, including human African trypanosomiasis, commonly known as sleeping sickness. The company is based in the United States and has focused its development activities on advancing clinical programs rather than marketing commercially approved products. Howard J. Jaffe, M.D., has been associated with the company’s leadership.

Key Stats

• Today's Range: $0.0005 to $0.0007
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 569 shs
• Average Volume: 4,250 shs
• Market Capitalization: $7.92 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/13/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PXMD
• CIK: 1811623
• Web: www.paxmedica.com
• Phone: 914-987-2876
• Fax: N/A
• Employees: 6
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): ($6.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,167.89%
• Return on Assets: -560.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 11,312,000
• Free Float: 11,199,000
• Market Cap: $7.92 thousand
• Optionable: Not Optionable
• Beta: -0.99